BioMarin Pharmaceutical Inc. Working Capital

Working Capital of BMRN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Working Capital growth rates and interactive chart. Working capital, also known as net working capital (NWC), is the difference between a company’s current assets, such as cash, accounts receivable (customers’ unpaid bills) and inventories of raw materials and finished goods, and its current liabilities, such as accounts payable. Net operating working capital is a measure of a company's liquidity and refers to the difference between operating current assets and operating current liabilities. In many cases these calculations are the same and are derived from company cash plus accounts receivable plus inventories, less accounts payable and less accrued expenses. Working capital is a measure of a company's liquidity, operational efficiency and its short-term financial health. If a company has substantial positive working capital, then it should have the potential to invest and grow. If a company's current assets do not exceed its current liabilities, then it may have trouble growing or paying back creditors, or even go bankrupt.

Highlights and Quick Summary

  • Working Capital for the quarter ending March 31, 2022 was $1.9 Billion (a 9.8% increase compared to previous quarter)
  • Year-over-year quarterly Working Capital decreased by -0.57%
  • Annual Working Capital for 2021 was $1.73 Billion (a -6.22% decrease from previous year)
  • Annual Working Capital for 2020 was $1.85 Billion (a 83.25% increase from previous year)
  • Annual Working Capital for 2019 was $1.01 Billion (a -34.18% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Working Capital of BioMarin Pharmaceutical Inc.

Most recent Working Capitalof BMRN including historical data for past 10 years.

Interactive Chart of Working Capital of BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. Working Capital for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $1,904.0
2021 $1,734.0 $1,797.0 $1,915.0 $1,859.0 $1,734.0
2020 $1,849.67 $1,884.29 $1,834.26 $1,295.78 $1,849.0
2019 $1,009.64 $1,365.61 $1,367.34 $1,415.87 $1,009.0
2018 $1,532.97 $1,569.19 $1,475.12 $1,467.64 $1,533.0
2017 $1,390.63 $1,632.5 $1,084.52 $1,012.58 $1,390.0
2016 $982.48 $1,289.24 $741.37 $604.78 $982.48
2015 $644.18 $785.1 $866.23 $1,217.22 $644.18
2014 $1,161.9 $871.27 $1,053.51 $1,090.37 $1,161.9
2013 $954.15 $545.85 $578.68 $579.02 $954.15
2012 $573.0 $584.46 $561.54 $393.58 $573.0
2011 $375.68 $403.77 $432.08 $375.68

Business Profile of BioMarin Pharmaceutical Inc.

Sector: Healthcare
Industry: Biotechnology
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.